Taking cellular immunotherapy to the next level

We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).

blue_cell

Pioneering, developing and manufacturing

Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK-cell production processes.During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.

Press releases

Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments

12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf

Glycostem and Ghent University sign license agreement on NK cell therapy technology

17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn

Glycostem announces treatment of first patient in pivotal phase I/IIa trial

15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for th